D

DBV Technologies SA
D

DBVT

0.60200
USD
-0.01
(-1.57%)
Market Open
Volume
1,394
EPS
-1
Div Yield
-
P/E
-1
Market Cap
57,915,016
Related Instruments
    A
    ALDX
    -0.06000
    (-1.41%)
    4.20000 USD
    D
    DBVT
    0.00000
    (0.00%)
    0.58000 USD
    K
    KALV
    -0.33000
    (-3.36%)
    9.48000 USD
    S
    SLDB
    -0.45000
    (-8.46%)
    4.87000 USD
    More
News

Title: DBV Technologies SA

Sector: Healthcare
Industry: Biotechnology
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.